AstraZeneca PLC provided earnings guidance for the fiscal year 2022. The company expects total revenue to increase by a high teens percentage and Core EPS is expected to increase by a mid-to-high twenties percentage.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,148 GBX | -0.15% | -1.92% | +14.45% |
May. 16 | AstraZeneca's Sipavibart Prevents COVID-19 in Immunocompromised Patients in Phase 3 Trial | MT |
May. 16 | Global markets live: Cisco, EasyJet, Roche, Netflix, Amazon... |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.45% | 239B | |
+32.36% | 694B | |
+30.74% | 593B | |
-1.60% | 371B | |
+20.07% | 331B | |
+6.04% | 290B | |
+10.07% | 209B | |
-3.11% | 209B | |
+9.27% | 169B | |
+0.45% | 164B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca PLC Provides Earnings Guidance for the Fiscal Year 2022